logo
Covalon Reports Fifth Consecutive Quarter of Positive Earnings

Covalon Reports Fifth Consecutive Quarter of Positive Earnings

Yahoo28-05-2025

Year-To-Date Revenue Grew 21% and Year-To-Date Adjusted EBITDA Increased by 57%
MISSISSAUGA, Ontario, May 28, 2025--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2025 second quarter results for the period ended March 31, 2025, along with a number of important recent achievements and highlights.
Brent Ashton, Covalon's Chief Executive Officer, reported, "In the past few months, the Covalon team has delivered on several of our key priorities that have led to expanded sales with new and existing customers, new agreements with key strategic partners, and exciting new clinical evidence generation.
In the first six months of our 2025 fiscal year, Covalon has:
Grown revenue by 21%,
Grown Gross Profit by 12%
Reduced Operating Expenses by 8%
Increased Adjusted EBITDA by 57%
As stated last quarter, we fully anticipated our U.S. Advanced Wound Care sales channel to have a sequential quarter decline in Q2. This is not consequential, as we have a clear line of sight via in-house orders, forecasts and recent strategic partner sell out trends, to a strong Q3 and second half.
Covalon recently signed a major distribution agreement with our longstanding strategic partner, Paul Hartmann USA, for ColActive Plus® and ColActive Plus® with Silver advanced wound care dressings. Covalon's U.S. Advanced Wound Care sales channel has been an important growth driver for the Company, and our first half of FY'25 was double the revenue from the same period two years ago.
Our U.S. Vascular Access and Surgical Consumables sales channel had excellent sequential quarterly growth of 19%, and year to date is up 46% vs. the prior year, led by significant growth from Covalon's VALGuard® Vascular Access Line Guard product. New clinical evidence on Covalon's VALGuard® will be presented at two prestigious scientific meetings in the fall and is advancing through the publication process in a major, well-regarded academic journal. This will be a significant accelerator to the surge in adoption that we have seen with major U.S. hospitals.
We have also made significant headway in our International sales channel, and our Q2 revenue of $2.3 million marked our highest quarterly revenue for International in more than five years, and has grown 44% year to date.
In a volatile and complex global trade environment, Covalon's North American-centric manufacturing strategy has yielded no tariff-related costs to date, and the Company sees the current tariff environment as a competitive advantage.
Covalon is in a stronger position than it has ever been, with profitable operations and a clean balance sheet with more than $18 million in cash and no debt. We have retained a highly regarded financial and strategic advisor to identify merger and acquisition opportunities and unlock value for all shareholders. Our accelerated focus on market development is generating exciting results. I see a clear path for Covalon to become a major player in the lucrative healthcare spaces we operate in."
Q2 FY'25 Financial Highlights
Revenue of $7.6 million led by strong growth in the U.S. Vascular Access and Surgical Consumables business as well as the International business
Adjusted EBITDA of $0.6 million – Covalon's 5th consecutive quarter of profitability
Strong free cash flow generation of $0.6 million
Recent Covalon Achievements and Highlights
Exciting results from an impactful clinical evidence study by a nursing research team at a large United States children's hospital have been selected for presentation at two prestigious scientific meetings this fall and are advancing through the final stages of the publication process in a major, well-regarded academic journal. Shared via the following press release:https://ir.covalon.com/news/news-details/2025/Covalon-Announces-Exciting-New-Clinical-Research-Evaluating-VALGuard-Vascular-Access-Line-Guard/default.aspx
Signed a new distribution agreement with longstanding strategic partner Paul Hartmann USA for ColActive Plus® and ColActive Plus® with Silver advanced wound care dressings.
The Company initiated work with Origin Merchant Partners to pursue strategic options to maximize shareholder value and expand the reach of our innovative medical technologies. Shared via the following press release:https://ir.covalon.com/news/news-details/2025/Covalon-Retains-Financial-and-Strategic-Advisor-to-Advise-on-Shareholder-Value-Enhancing-Opportunities/default.aspx
Promoted Kim Crooks to be Chief Operating Officer and join Covalon's Board of Directors. Promoted Dr. Kate Evely to be Vice President of Clinical Affairs. Both Ms. Crooks and Dr. Evely have been instrumental in the recent success of the company. Ms. Crooks' announcement can be found athttps://ir.covalon.com/news/news-details/2025/Covalon-Announces-Promotion-of-Kim-Crooks-to-Chief-Operating-Officer-and-Appointment-to-Board-of-Directors/default.aspx
Successful investor presentations and meetings at Planet Microcap Showcase: Vegas 2025 and the 2025 Bloom Burton Healthcare Investor Conference. Presentation content and audio can be found here:https://event.summitcast.com/view/YNz6mnmEsXyrdRxb78w2nX/guest_book?session_id=HcJChMRczMNFyjGQ8jTLb3
The Company has successfully navigated the volatile global tariff environment with no additional tariff-related costs in Q2, FY'25. Based on the current tariff environment, Covalon does not anticipate any material future tariff costs related to the 2025 tariff changes. As the largest North American manufacturer of collagen wound care dressings, the Company sees the current tariff environment as a competitive advantage for its U.S. Advanced Wound Care business.
Conference Call Scheduled
A conference call and webcast to discuss Covalon's fiscal 2025 Q2 financial results will be held on Wednesday, May 28 at 8:30am Eastern Time. To view, listen to, and participate in the live webcast, please follow the link below:
https://events.q4inc.com/attendee/971812521
To listen and participate via the conference call, please dial:
North American Toll-Free: 1-800-549-8228Local (Toronto): 289-819-1520Local (New York): 646-564-2877Conference ID: 92114
Participants will be able to ask questions of Company management during the Q&A portion of the conference call.
A recording of the call will also be available on www.covalon.com under Financials on the Investors tab.
Q2 Financial Overview
For the three-month period ending March 31, 2025:
Total revenue decreased to $7,585,968 compared to $8,388,022 in the same period of the prior year. The decrease in product revenue was primarily driven by a normalization of channel inventory for one of the Company's Advanced Wound Care U.S. strategic partners.
The Company reported a gross margin of 55% for the period, compared to 63% in the same period of the prior year. The year-over-year decrease in gross margin was primarily driven by changes in geographic and product mix.
The operating expenses were relatively consistent at $3,857,686, compared to $3,827,704 in the same period of the prior period.
The operations department covers expenses related to quality control, quality assurance, production, and regulatory activities. Operations expenses increased slightly to $451,471 compared to $423,239 in the same period of the prior year. This increase was primarily due to higher employee training costs incurred in the current period, which helped to strengthen operational efficiency and compliance with regulatory standards.
Research and development expenses decreased to $320,459 compared to $450,510 in the same period of the prior year primarily due to lower patent & trademark costs as the costs can vary by quarter and fiscal year due to the timing and region of the renewals.
Sales and marketing expenses were flat at $1,250,162, compared to $1,262,960 in the same period of the prior year. The Company continues to optimize sales and marketing strategies to accelerate demand for the company's products.
General and administrative expenses increased to $1,835,594 compared to $1,690,995 in the same period of the prior year, reflecting higher professional service fees. Wages, benefits, and consulting fees (for all departments) included non-cash share-based compensation expenses of $65,540, down from $81,464 in the prior year. These costs reflect outstanding stock options and deferred share units (DSUs) and their respective fair values.
For the six-month period ending March 31, 2024:
Total revenue increased to $15,751,948 compared to $13,076,667 in the same period of the prior year, with double digit growth in the 3 main sales channels the company is focused on – the U.S. Advanced Wound Care sales channel, the U.S. Vascular Access and Surgical Consumables sales channel and the International sales channel.
Gross Margin decreased to 58% compared to 62% in the same period for the prior year. During the six months ended March 31, 2025, the Company recorded a $114,645 release in inventory provision due to revised obsolescence estimates, compared to an inventory provision of $482,095 recorded during the six months ended March 31, 2024. Gross margin fluctuates as a result of the mix of products sold in any given quarter, or year, by product type and geography.
Operating expenses decreased to $7,537,484 compared to $8,147,756 in the same period of the prior year. The majority of this decrease, is attributable to reduced sales and marketing expenses. Additional spending reductions were realized across operations, research and development, and general and administrative functions, reflecting the Company's continued focus on cost efficiency and disciplined expense management.
Operations expenses decreased to $822,540 from $1,053,952 in the same period of the prior year. The reduction was primarily attributable to the timing of expenses related to product development initiatives that were recognized in the prior year.
Research and development expenses decreased to $693,798 compared to $761,921 in the same period for the prior year, mainly due to lower patent and trademark costs.
Sales and marketing costs decreased to $2,459,982 compared to $2,909,263 in the same period of the prior year, due primarily to lower staffing levels.
General and administrative expenses increased to $3,561,164 compared to $3,422,620 in the same period in the prior year, due primarily to higher spending on professional service fees.
Wages, benefits, and consulting fees (for all departments) include a non-cash compensation expense of $156,063, down from $197,393 in the prior year. These costs reflect outstanding stock options and deferred share units (DSUs) and their respective fair values.
Statement of Operations
The following audited table presents Covalon's consolidated statements of operations for the three-month and six-month periods ended March 31, 2025, and 2024.
Three months endedMarch 31,
Six months endedMarch 31,
2025
2024
2025
2024
Revenue
Product
$7,585,968
$8,388,022
$15,663,908
$12,963,789
Development and consulting services
-
-
5,826
56,640
Licensing and royalty fees
-
25,588
82,214
56,238
Total revenue
7,585,968
8,413,610
15,751,948
13,076,667
Cost of sales
3,446,462
3,103,148
6,617,976
4,917,668
Gross profit
4,139,506
5,310,462
9,133,972
8,158,999
Operating expenses
Operations
451,471
423,239
822,540
1,053,952
Research and development activities
320,459
450,510
693,798
761,921
Sales, marketing and agency fees
1,250,162
1,262,960
2,459,982
2,909,263
General and administrative
1,835,594
1,690,995
3,561,164
3,422,620
3,857,686
3,827,704
7,537,484
8,147,756
Finance expenses (income)
(147,319)
22,340
(188,387)
12,376
Loss/(gain) on finance lease receivable
-
-
149,690
(610,008)
Net income
$429,139
$1,460,418
$1,635,185
$608,875
Other comprehensive income (loss)
Amount that may be reclassified to profit or loss
Foreign currency translation adjustment
(40,155)
576,178
1,810,299
188,905
Total comprehensive income
$388,984
$2,036,596
$3,445,484
$797,780
Income per common share
Basic income per share (Note 16)
$0.02
$0.06
$0.06
$0.02
Diluted income per share (Note 16)
$0.02
$0.06
$0.06
$0.02
Non-GAAP Financial Measures
This press release makes reference to certain non-GAAP measures. These measures are not recognized or defined measures under IFRS Accounting Standards, do not have standardized meaning prescribed by IFRS Accounting Standards and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional financial information to complement those IFRS Accounting Standards measures by providing further understanding of our results of operations from management's perspective. Accordingly, these measures should not be considered in isolation or as a substitute for analysis of our financial information reported under IFRS Accounting Standards. The non-GAAP financial measures, adjustments, and reasons for adjustments should be carefully evaluated as these measures have limitations as analytical tools and should not be used in substitution for an analysis of the Company's results under IFRS Accounting Standards. We use non-GAAP measures including "Adjusted Gross Margin" and "Adjusted EBITDA" to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS Accounting Standards measures. We believe that securities analysts, investors and other interested parties frequently use non-GAAP measures in the evaluation of issuers. Our management also uses non-GAAP measures in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of management compensation. The following non-GAAP financial measures are presented in this news release, and a description of the calculation for each measure is included below:
Adjusted Gross Margin is defined as gross profit before operating expenses, plus depreciation and amortization included in cost of sales, plus inventory provision amounts.
Adjusted EBITDA as earnings (loss) before interest expense (income), depreciation and amortization, stock-based compensation, inventory provisions (reversals), gain (loss) on finance lease receivable, and loss (gain) on disposal of property and equipment.
You should also be aware that the Company may recognize income or incur expenses in the future that are the same as, or similar to some of the adjustments in these non-GAAP financial measures. Because these non-GAAP financial measures may be defined differently by other companies in our industry, our definitions of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies, thereby diminishing their utility.
The table below provides a reconciliation of gross profit before operating expenses under IFRS Accounting Standards in the consolidated financial statements to Adjusted Gross Margin for the three-month and six-month periods ended March 31, 2025, and 2024. Management believes that Adjusted Gross Margin is useful in assessing the performance of the Company's ongoing operations and its ability to generate cash flows from period to period. The adjusting items below are considered to be outside of the Company's core operating results, and these items can distort the trends associated with the Company's ongoing performance, even though some of those expenses may recur.
Three months endedMarch 31,
Six months endedMarch 31,
2025
2024
2025
2024
Gross profit
$4,139,506
$5,310,462
9,133,972
$8,158,999
Add: Depreciation and amortization
43,728
58,322
113,353
110,870
Add: Inventory provisions (reversals)
-
674,866
(114,645)
482,095
Adjusted Gross Margin
4,183,234
6,043,650
9,132,680
8,751,964
Adjusted Gross Margin (%)
55%
72%
58%
67%
The table below provides a reconciliation of net income under IFRS Accounting Standards in the unaudited condensed consolidated interim financial statements to Adjusted EBITDA for the three-month and six-month periods ended March 31, 2025, and 2024. Management believes that these non-GAAP measures are useful in assessing the performance of the Company's ongoing operations and its ability to generate cash flows to fund its cash requirements from period to period. The adjusting items below are considered to be outside of the Company's core operating results, and these items can distort the trends associated with the Company's ongoing performance, even though some of those expenses may recur.
Three months endedMarch 31,
Six months endedMarch 31
2025
2024
2025
2024
Net income
$429,139
$1,460,418
$1,635,185
$608,875
Add: Finance expense (gains)
(147,319)
22,340
(188,387)
12,376
Add: Depreciation and amortization
233,621
247,756
490,746
487,950
Add: Stock based compensation
65,540
81,464
156,063
197,393
Add: Inventory provisions (reversals)
-
674,866
(114,645)
482,095
Add: Impairment of intangible asset
-
101,577
-
176,025
Add: (Gain)/loss of finance lease receivable
-
-
149,690
(610,008)
Adjusted EBITDA
$580,981
$2,588,421
$2,128,650
$1,354,706
About Covalon
Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
(1)
See "Non-GAAP Measures" below, including for a reconciliation of the non-GAAP measures used in this release to the most comparable IFRS Accounting Standards measures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250528594851/en/
Contacts
To learn more about Covalon, please contact:Investor Relations, Covalon Technologies Ltd.Email: investors@covalon.com Website: https://covalon.com/

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New AI-Detection Engineering Assistant from Cymulate Automates SIEM Rule Validation for SecOps and Blue Teams
New AI-Detection Engineering Assistant from Cymulate Automates SIEM Rule Validation for SecOps and Blue Teams

Yahoo

time21 minutes ago

  • Yahoo

New AI-Detection Engineering Assistant from Cymulate Automates SIEM Rule Validation for SecOps and Blue Teams

Innovation streamlines threat detection engineering with automated testing, control integrations and enhanced detections NEW YORK & TEL AVIV, Israel, June 09, 2025--(BUSINESS WIRE)--Cymulate, the leader in threat exposure validation, today announced the release of its powerful new AI-powered detection engineering assistant for security information and event management (SIEM) rule threat coverage validation. Now, the Cymulate Platform automates and streamlines the detection engineering process for blue teams and SecOps, allowing them to build, test and optimize threat detection with AI-assisted live-data attack simulations and customized threat detection. With this launch, Cymulate eliminates the friction of manual detection validation by automating the correlation and testing process, answering the two most important questions in modern detection engineering: "Does my rule work?" and "What threats does it actually cover?" This enables SecOps and blue teams to identify coverage gaps and tune rules in minutes, whereas previously, mapping detection rules to relevant threats required hours of manual effort, reviewing rule logic, identifying threat coverage and testing scenarios one by one. By automating the correlation between detection rules and Cymulate attack scenarios leveraging advanced AI analysis, organizations can now ensure their SIEM rules are continuously validated against real-world threats and optimized with precision. "Detection engineering doesn't have to be complicated, and Cymulate applies AI to help organizations across the globe drastically simplify their process. What once required lengthy back-and-forth between detection engineers and red teamers can now be done in just minutes," said Avihai Ben-Yossef, co-founder and CTO of Cymulate. "As today's threat actors look to exploit security gaps faster and with more sophisticated methods, it's clear that security teams need a continuous focus on threat detection. Cymulate is proud to set the standard for exposure validation, and our new SIEM solution applies the latest AI-driven automation technology to address some of the most complicated areas in detection engineering." The Cymulate platform now features deeper integrations with SIEMs and AI-powered analysis to map detection rules to its extensive library of more than 100,000 attack scenarios. Cymulate validates SIEM detection rules through live-data attack simulations, which test and validate both detection logic and the collection of logs and events required to support the rule. The Cymulate Exposure Validation Platform helps SecOps and blue teams: Identify gaps in their detection capabilities before adversaries can go unnoticed Operationalize threat intel to build custom threat validation Understand when and why existing threat detection fails to trigger Accelerate detection tuning with relevant indicators of behavior, pre-built Sigma rules and EDR rule Maximize visibility and coverage across the MITRE ATT&CK® framework To learn more about the Cymulate Exposure Validation Platform, visit About Cymulate Cymulate, the leader in security and exposure validation, provides the single source of truth for threat exposure and the actions required to close security gaps before attackers can exploit them. More than 1,000 customers worldwide rely on the Cymulate platform to baseline their security posture and strengthen cyber resilience with continuous discovery, validation, prioritization, and guided remediation of security weaknesses. Cymulate automates advanced offensive security testing to validate controls, threats, and attack paths. As an open platform, Cymulate integrates with existing security and IT infrastructure and drives the workflows of the exposure management process. For more information, visit View source version on Contacts Media Contact: Melissa CifarelliAccount Directorprcymulate@

KI Celebrates Best of NeoCon 2025 Recognition for the Cogni Classroom Chair
KI Celebrates Best of NeoCon 2025 Recognition for the Cogni Classroom Chair

Yahoo

time41 minutes ago

  • Yahoo

KI Celebrates Best of NeoCon 2025 Recognition for the Cogni Classroom Chair

Reinforcing KI's Commitment to Innovation in Flexible and Active Learning Spaces. GREEN BAY, Wis., June 09, 2025--(BUSINESS WIRE)--KI is proud to announce its success at this year's Best of NeoCon awards competition, with one of its newest innovations receiving Silver honors at North America's most prestigious commercial interiors awards program. This recognition reinforces KI's commitment to thoughtful, flexible and forward-thinking design solutions for today's evolving learning, working and healing environments. "We are incredibly honored to be recognized by the Best of NeoCon judges for the Cogni Classroom Chair," said Tony Besasie, chief marketing and sales officer at KI. "The Best of NeoCon Silver Award validates the passion and purpose our design and engineering teams bring to each product we develop. Every piece reflects KI's belief in creating intelligent, adaptable solutions that meet the real needs of our customers across industries." Cogni™ classroom seating redefines the student experience with intuitive support, durable construction and the flexibility required in today's active learning spaces. Designed with ergonomic comfort and motion in mind, Cogni encourages natural movement to promote student engagement and focus. "With Cogni, we set out to rethink what classroom seating could be," said Besasie. "We know that movement is essential to focus and learning. Cogni encourages that movement—offering intuitive comfort that adapts to the learner, not the other way around. It's a thoughtful response to how students truly engage in today's classrooms." This recognition comes as KI marks its final NeoCon showcase at The Mart before moving to its new showroom in Fulton Market in 2026. "As we reflect on our legacy at The Mart and look ahead to our future at Fulton Market, it is especially meaningful to be honored this year," said Besasie. "This moment encapsulates KI's evolution, rooted in design excellence and always looking forward." ABOUT KI KI manufactures innovative furniture for education, healthcare, government and corporate markets. The employee-owned company is headquartered in Green Bay, Wisconsin, with sales and manufacturing facilities worldwide. KI tailors products and service solutions to the specific needs of each customer through its unique design and manufacturing philosophy. For more information, visit View source version on Contacts Media Contact: Shelly SchumacherVice President, Public RelationsNelson Schmidt Inc.262-305-1713sschumacher@

TALON METALS ANNOUNCES UPSIZED $39 MILLION FINANCING COMPRISED OF $25 MILLION BROKERED PRIVATE PLACEMENT AND CONCURRENT $14 MILLION NON-BROKERED PRIVATE PLACEMENT
TALON METALS ANNOUNCES UPSIZED $39 MILLION FINANCING COMPRISED OF $25 MILLION BROKERED PRIVATE PLACEMENT AND CONCURRENT $14 MILLION NON-BROKERED PRIVATE PLACEMENT

Yahoo

time41 minutes ago

  • Yahoo

TALON METALS ANNOUNCES UPSIZED $39 MILLION FINANCING COMPRISED OF $25 MILLION BROKERED PRIVATE PLACEMENT AND CONCURRENT $14 MILLION NON-BROKERED PRIVATE PLACEMENT

/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ ROAD TOWN, Tortola, British Virgin Islands, June 9, 2025 /CNW/ - Talon Metals Corp. (TSX: TLO) (OTC Pink: TLOFF) ("Talon" or the "Company") is pleased to announce that as a result of strong investor demand, the Company has amended its agreement with Canaccord Genuity Corp. ("Canaccord Genuity") on behalf of a syndicate of underwriters (the "Underwriters") to increase the size of its previously announced "bought deal" private placement of units of the Company (the "LIFE Units") to raise gross proceeds of $25,300,000 (the "LIFE Offering"), consisting of 115,000,000 LIFE Units at a price of $0.22 per LIFE Unit (the "Offering Price"). Concurrent with the LIFE Offering, the Company plans to complete a non-brokered private placement of up to 62,227,274 units of the Company (the "Non-LIFE Units" and, together with the LIFE Units, the "Units") at the Offering Price per Non-LIFE Unit for aggregate gross proceeds of up to approximately $13,690,000 (the "Non-LIFE Offering" and, together with the LIFE Offering, the "Offerings"). The Non-LIFE Units will be issued on the same terms as the LIFE Units. The Non-LIFE Units may be offered to purchasers resident in Canada pursuant to applicable prospectus exemptions, other than the Listed Issuer Financing Exemption (as defined below), in accordance with applicable laws, and may also be offered in other qualifying jurisdictions outside of Canada on a private placement basis pursuant to relevant prospectus or registration exemptions in accordance with applicable laws. Any securities issued under the Non-LIFE Offering to purchasers resident in Canada will be subject to a hold period in accordance with applicable Canadian securities laws, expiring four months and one day following the issue date of the Non-LIFE Units. The Non-LIFE Offering will be completed with certain directors, officers and affiliates of Pallinghurst Nickel International Ltd. Each Unit will be comprised of one common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a "Warrant"). Each Warrant will entitle the holder thereof to acquire one Common Share (a "Warrant Share") at a price of $0.28 per Warrant Share for a period of 36 months from the closing of the LIFE Offering or Non-LIFE Offering, as applicable. In the event that the closing price of the Common Shares on the Toronto Stock Exchange (the "TSX") (or such other Canadian stock exchange on which the Common Shares are then listed) for twenty (20) consecutive trading days exceeds $0.56, the Company may, within 10 business days of the occurrence of such event, deliver a notice (including by way of a news release) to the holders of Warrants accelerating the expiry date of the Warrants to the date that is 30 days following the date of such notice. The LIFE Units will be offered pursuant to Part 5A of National Instrument 45-106 – Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the "Listed Issuer Financing Exemption"), to purchasers resident in Canada (other than the province of Québec), and in other qualifying jurisdictions outside of Canada that are mutually agreed to by the Company and the Underwriters on a private placement basis pursuant to relevant prospectus or registration exemptions in accordance with applicable laws. The securities issued under the LIFE Offering to Canadian subscribers will not be subject to a hold period in Canada. There is an amended and restated offering document related to the LIFE Offering (the "Offering Document") that can be accessed under the Company's profile on SEDAR+ at and on the Company's website at Prospective investors should read the Offering Document before making an investment decision. The Company intends to use the net proceeds from the Offerings to advance the Tamarack Nickel Project and for general and administrative expenses and working capital purposes, as further described in the Offering Document. The Offerings are expected to close on or about June 19, 2025, or such other date as the Company and Canaccord Genuity may agree (the "Closing Date"). The Non-LIFE Offering may close on a date subsequent to or prior to the closing date of the LIFE Offering at the discretion of the Company. The Offerings are subject to the Company receiving all necessary regulatory approvals, including the approvals of the TSX. The closing of the LIFE Offering is not conditional upon closing of the Non-LIFE Offering, and the closing of the Non-LIFE Offering is not conditional upon closing of the LIFE Offering. The Units (and the underlying securities) to be offered pursuant to the Offerings have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About Talon Talon is a TSX-listed base metals company in a joint venture with Rio Tinto on the high-grade Tamarack Nickel-Copper-Cobalt Project located in central Minnesota. Talon's shares are also traded in the US over the OTC market under the symbol TLOFF. The Tamarack Nickel Project comprises a large land position (18km of strike length) with additional high-grade intercepts outside the current resource area. Talon has an earn-in right to acquire up to 60% of the Tamarack Nickel Project and currently owns 51%. Talon is focused on (i) expanding and infilling its current high-grade nickel mineralization resource prepared in accordance with NI 43-101 to shape a mine plan for submission to Minnesota regulators, and (ii) following up on additional high-grade nickel mineralization in the Tamarack Intrusive Complex. Talon has a neutrality and workforce development agreement in place with the United Steelworkers union. Talon's Beulah Mineral Processing Facility in Mercer County was selected by the US Department of Energy for US$114.8 million funding grant from the Bipartisan Infrastructure Law and the US Department of Defense awarded Talon a grant of US$20.6 million to support and accelerate Talon's exploration efforts in both Minnesota and Michigan. Talon has well-qualified experienced exploration, mine development, external affairs and mine permitting teams. Forward-Looking Statements This news release contains certain "forward-looking statements". All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements reflect the current expectations and beliefs of the Company based on information currently available to the Company. Such forward-looking statements include statements relating to the Offerings, including the completion and anticipated timing for completion of the Offerings, the potential size of the Offerings, the Company's intended use of the net proceeds of the Offerings, the receipt of all necessary regulatory approvals, including the approvals of the TSX, and the Company's exploration and development plans. Forward-looking statements are subject to significant risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. SOURCE Talon Metals Corp. View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store